|
|
Article: Fosamax Demonstrates 10 Years of Bone Benefits in Longest Study of Osteoporosis Treatment to Date.
- Article from:
- Business Wire
- Article date:
- September 23, 2002
CopyrightCOPYRIGHT 2002 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Medical Writers
SAN ANTONIO--(BUSINESS WIRE)--Sept. 23, 2002
In the longest study of a non-hormonal osteoporosis therapy to date, Fosamax(R) (alendronate sodium) continued to help build spinal bone through 10 years of treatment of osteoporosis in postmenopausal women.
The results were presented today at the annual meeting of the American Society for Bone Mineral Research (ASBMR) in San Antonio, Texas.
"Having clinical data on the long-term effectiveness and safety of osteoporosis therapies is very important," said Henry G. Bone III, M.D., of the Michigan Bone and Mineral Clinic in Detroit. "The results of ...